These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25851117)

  • 1. Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective.
    Biswal S
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):136-43. PubMed ID: 25851117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea.
    Yeo QM; Crutchley R; Cottreau J; Tucker A; Garey KW
    Drugs Today (Barc); 2013 Apr; 49(4):239-52. PubMed ID: 23616951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crofelemer for the treatment of secretory diarrhea.
    Cottreau J; Tucker A; Crutchley R; Garey KW
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):17-23. PubMed ID: 22149578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crofelemer, a novel agent for treatment of secretory diarrhea.
    Crutchley RD; Miller J; Garey KW
    Ann Pharmacother; 2010 May; 44(5):878-84. PubMed ID: 20388859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels.
    Tradtrantip L; Namkung W; Verkman AS
    Mol Pharmacol; 2010 Jan; 77(1):69-78. PubMed ID: 19808995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.
    Castro JG; Chin-Beckford N
    Expert Rev Clin Pharmacol; 2015; 8(6):683-90. PubMed ID: 26517110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crofelemer: a review of its use in the management of non-infectious diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy.
    Frampton JE
    Drugs; 2013 Jul; 73(10):1121-9. PubMed ID: 23807722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons.
    Chordia P; MacArthur RD
    Expert Rev Gastroenterol Hepatol; 2013 Sep; 7(7):591-600. PubMed ID: 24070150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
    Macarthur RD; Hawkins TN; Brown SJ; Lamarca A; Clay PG; Barrett AC; Bortey E; Paterson C; Golden PL; Forbes WP
    HIV Clin Trials; 2013; 14(6):261-73. PubMed ID: 24334179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crofelemer for the treatment of chronic diarrhea in patients living with HIV/AIDS.
    Patel TS; Crutchley RD; Tucker AM; Cottreau J; Garey KW
    HIV AIDS (Auckl); 2013; 5():153-62. PubMed ID: 23888120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of antisecretory drugs for treating diarrheal diseases.
    Thiagarajah JR; Ko EA; Tradtrantip L; Donowitz M; Verkman AS
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):204-9. PubMed ID: 24316107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CFTR inhibitors for treating diarrheal disease.
    Thiagarajah JR; Verkman AS
    Clin Pharmacol Ther; 2012 Sep; 92(3):287-90. PubMed ID: 22850599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
    Gao JJ; Tan M; Pohlmann PR; Swain SM
    Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing novel antisecretory drugs to treat infectious diarrhea.
    de Hostos EL; Choy RK; Nguyen T
    Future Med Chem; 2011 Aug; 3(10):1317-25. PubMed ID: 21859305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CFTR chloride channel drug discovery--inhibitors as antidiarrheals and activators for therapy of cystic fibrosis.
    Verkman AS; Lukacs GL; Galietta LJ
    Curr Pharm Des; 2006; 12(18):2235-47. PubMed ID: 16787252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretory diarrhoea: mechanisms and emerging therapies.
    Thiagarajah JR; Donowitz M; Verkman AS
    Nat Rev Gastroenterol Hepatol; 2015 Aug; 12(8):446-57. PubMed ID: 26122478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisecretory drugs for diarrheal disease.
    Farthing MJ
    Dig Dis; 2006; 24(1-2):47-58. PubMed ID: 16699263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Botanical Drug Substance Crofelemer as a Model System for Comparative Characterization of Complex Mixture Drugs.
    Kleindl PA; Xiong J; Hewarathna A; Mozziconacci O; Nariya MK; Fisher AC; Deeds EJ; Joshi SB; Middaugh CR; Schöneich C; Volkin DB; Forrest ML
    J Pharm Sci; 2017 Nov; 106(11):3242-3256. PubMed ID: 28743606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide inhibitors of chloride channels for treating secretory diarrhea.
    Ma J; Ding X; Yin Y; Huang P
    Front Biosci (Landmark Ed); 2018 Jun; 23(10):1780-1788. PubMed ID: 29772528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crofelemer (Fulyzaq) for antiretroviral-induced diarrhea.
    Med Lett Drugs Ther; 2013 Jul; 55(1421):59-60. PubMed ID: 23863919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.